Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.
暂无分享,去创建一个
G. Bifulco | O. Werz | R. Riccio | R. De Simone | I. Bruno | M. G. Chini | D. Mueller | M. Chini
[1] R. Riccio,et al. Development of a second generation of inhibitors of microsomal prostaglandin E synthase 1 expression bearing the gamma-hydroxybutenolide scaffold. , 2008, Bioorganic & medicinal chemistry.
[2] O. Werz. 5-lipoxygenase: cellular biology and molecular pharmacology. , 2002, Current drug targets. Inflammation and allergy.
[3] Sunil Badve,et al. Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy , 2006, The Journal of pathology.
[4] O. Werz,et al. Inhibitors of the microsomal prostaglandin E(2) synthase-1 as alternative to non steroidal anti-inflammatory drugs (NSAIDs)--a critical review. , 2009, Current medicinal chemistry.
[5] G. Schneider,et al. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.
[6] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[7] Jilly F. Evans,et al. Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein , 2007, Science.
[8] J. Salmon,et al. Selective inhibition of arachidonate 5‐lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo , 1988, British journal of pharmacology.
[9] Chang-Guo Zhan,et al. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation. , 2008, The journal of physical chemistry. B.
[10] Alfonso T. García-Sosa,et al. Structure-based calculation of drug efficiency indices , 2007, Bioinform..
[11] H. Kolb,et al. The growing impact of click chemistry on drug discovery. , 2003, Drug discovery today.
[12] J. T. Metz,et al. Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.
[13] P. Paty,et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] B. Samuelsson,et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[15] Lihe Zhang,et al. A Convenient Preparation of 5‐Iodo‐1,4‐disubstituted‐1,2,3‐triazole: Multicomponent One‐Pot Reaction of Azide and Alkyne Mediated by CuI—NBS. , 2008 .
[16] Robert Fletterick,et al. The structure of mammalian 15-lipoxygenase reveals similarity to the lipases and the determinants of substrate specificity , 1997, Nature Structural Biology.
[17] Xiaohua Jiang,et al. A fragment-based in situ combinatorial approach to identify high-affinity ligands for unknown binding sites. , 2010, Angewandte Chemie.
[18] R. DuBois,et al. PROSTAGLANDINS AND CANCER , 2005, Gut.
[19] N. Méthot,et al. Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. , 2005, Bioorganic & medicinal chemistry letters.
[20] Calvin Yu-Chian Chen,et al. Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping , 2009 .
[21] V. Fokin,et al. Copper-catalyzed reaction cascade: direct conversion of alkynes into N-sulfonylazetidin-2-imines. , 2006, Angewandte Chemie.
[22] S. Cho,et al. 3D-QSAR study of microsomal prostaglandin E2 synthase(mPGES-1) inhibitors , 2007 .
[23] P. McGettigan,et al. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.
[24] Wolfgang Albrecht,et al. Licofelone Suppresses Prostaglandin E2 Formation by Interference with the Inducible Microsomal Prostaglandin E2 Synthase-1 , 2008, Journal of Pharmacology and Experimental Therapeutics.
[25] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[26] Chang-Guo Zhan,et al. Human Microsomal Prostaglandin E Synthase-1 (mPGES-1) Binding with Inhibitors and the Quantitative Structure-Activity Correlation , 2008, J. Chem. Inf. Model..
[27] Luke G Green,et al. A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. , 2002, Angewandte Chemie.
[28] G. Burmester,et al. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. , 2001, The American journal of medicine.
[29] Ralf Morgenstern,et al. Structural basis for detoxification and oxidative stress protection in membranes. , 2006, Journal of molecular biology.
[30] J. Mancini,et al. Microsomal Prostaglandin E2 Synthase‐1 (mPGES‐1): A Novel Antiinflammatory Therapeutic Target , 2008 .
[31] QM and Pharmacophore based 3D-QSAR of MK886 Analogues against mPGES-1 , 2008 .
[32] J. Gierse,et al. Selective inducible microsomal prostaglandin E(2) synthase-1 (mPGES-1) inhibitors derived from an oxicam template. , 2010, Bioorganic & medicinal chemistry letters.
[33] Hans Peter Nestler. Combinatorial chemistry and fragment screening--two unlike siblings? , 2005, Current drug discovery technologies.
[34] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[35] J. Moses,et al. The Growing Applications of Click Chemistry , 2007 .
[36] K. Sharpless,et al. Copper‐Catalyzed Synthesis of N‐Sulfonyl‐1,2,3‐triazoles: Controlling Selectivity. , 2007 .
[37] M. G. Finn,et al. In situ Click Chemistry: Probing the Binding Landscapes of Biological Molecules , 2010 .
[38] N. Méthot,et al. Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[39] Ralf Morgenstern,et al. Human Microsomal Prostaglandin E Synthase-1 , 2003, Journal of Biological Chemistry.
[40] Yves Bureau,et al. Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model , 2003, The Journal of Immunology.
[41] G. Schneider,et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5‐lipoxygenase products , 2007, British journal of pharmacology.
[42] Makoto Murakami,et al. Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.
[43] Fan Zhang,et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] M. Jett,et al. Effect of 5‐lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells , 2008, The FEBS journal.
[45] W. Dehaen,et al. A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. , 2004, Organic letters.
[46] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[47] A. Hamza,et al. Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. , 2010, The journal of physical chemistry. B.
[48] V. Fokin,et al. Practical Synthesis of Amides from in situ Generated Copper(I) Acetylides and Sulfonyl Azides. , 2006 .
[49] Substituted Phenanthrene Imidazoles as Potent, Selective, and Orally Active mPGES-1 Inhibitors. , 2008 .
[50] Johan Wouters,et al. Structural insights into human 5-lipoxygenase inhibition: combined ligand-based and target-based approach. , 2006, Journal of medicinal chemistry.
[51] C. Funk,et al. Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.
[52] Ralf Morgenstern,et al. Structural basis for induced formation of the inflammatory mediator prostaglandin E2 , 2008, Proceedings of the National Academy of Sciences.